RAPP (Rapport Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RAPP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2026-08-26 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2026-08-26 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | — | — |
| 2026-08-20 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | — | — |
| 2026-08-12 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2026-07-29 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2026-07-15 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2026-07-01 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2026-07-01 | Cheryl Gault | Chief Operating Officer | Sell | — | — |
| 2026-06-10 | Wendy B. Young | Director | A | — | — |
| 2026-06-10 | ROBERT J PEREZ | Director | A | — | — |
| 2026-06-10 | JAMES HEALY | Director | A | — | — |
| 2026-06-10 | Reid M Huber | Director | A | — | — |
| 2026-06-10 | Ramiro Sanchez | Director | A | — | — |
| 2026-06-10 | STEVEN M PAUL | Director | A | — | — |
| 2026-06-10 | JOHN MARAGANORE | Director | A | — | — |
| 2026-06-10 | Paul M Silva | Director | A | — | — |
| 2026-05-28 | Third Rock Ventures GP VI, L.P. | 10%+ Owner | Sell | — | — |
| 2026-05-13 | TRV GP V, LLC | 10%+ Owner | Sell | — | — |
| 2026-05-11 | Third Rock Ventures VI, L.P. | 10%+ Owner | Sell | — | — |
| 2026-04-21 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | — | — |
| 2026-04-21 | Third Rock Ventures V, L.P. | 10%+ Owner | Sell | — | — |
| 2026-04-14 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | — | — |
| 2026-04-09 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | — | — |
| 2026-03-26 | Krishnaswamy Yeleswaram | Chief Development Officer | Sell | — | — |
| 2026-03-09 | Cheryl Gault | Chief Operating Officer | Sell | — | — |
| 2026-02-19 | David Bredt | Chief Scientific Officer | MIXED | — | — |
| 2026-02-19 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2026-02-04 | David Bredt | Chief Scientific Officer | A | — | — |
| 2026-02-04 | Krishnaswamy Yeleswaram | Chief Development Officer | A | — | — |
| 2026-02-04 | Troy A. Ignelzi | Chief Financial Officer | A | — | — |
| 2026-02-04 | Abraham Ceesay | Chief Executive Officer | A | — | — |
| 2026-02-04 | Cheryl Gault | Chief Operating Officer | A | — | — |
| 2026-02-04 | Jeffrey Sevigny | Chief Medical Officer | A | — | — |
| 2026-01-22 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2026-01-16 | David Bredt | Chief Scientific Officer | Sell | — | — |
| 2026-01-05 | Krishnaswamy Yeleswaram | Chief Development Officer | MIXED | — | — |
| 2026-01-05 | David Bredt | Chief Scientific Officer | MIXED | — | — |
| 2025-12-18 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2025-12-16 | David Bredt | Chief Scientific Officer | Sell | — | — |
| 2025-12-01 | Cheryl Gault | Chief Operating Officer | MIXED | — | — |
| 2025-11-18 | David Bredt | Chief Scientific Officer | Sell | — | — |
| 2025-11-18 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2025-10-16 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2025-10-16 | David Bredt | Chief Scientific Officer | Sell | — | — |
| 2025-09-19 | Abraham Ceesay | Chief Executive Officer | Sell | — | — |
| 2025-09-17 | David Bredt | Chief Scientific Officer | Sell | — | — |
| 2025-09-15 | Reid M Huber | Director | Buy | — | — |
| 2025-09-15 | STEVEN M PAUL | Director | Buy | — | — |
| 2025-09-11 | Wendy B. Young | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 7,678,446 | — |
| — | 10%+ Owner | 7,406,951 | — |
| — | 10%+ Owner | 7,268,315 | — |
| — | 10%+ Owner | 7,249,743 | — |
| — | 10%+ Owner | 3,728,738 | — |
| — | Chief Executive Officer | 541,775 | — |
| — | Chief Scientific Officer | 389,275 | — |
| — | Chief Development Officer | 212,063 | — |
| — | Chief Operating Officer | 150,914 | — |
| — | Director | 39,661 | — |
| — | Director | 28,284 | — |
| — | Director | 20,400 | — |
| — | Chief Financial Officer | 10,000 | — |
| — | Director | 9,500 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RAPP quote page; the site-wide leaderboard is on the insider transactions hub.